Prominent examples include epidermal growth factor receptor (EGFR) kinase inhibitors (Afatinib, Gefitinib, and Osimertinib) for treating EGFR-mutated non-small cell carcinoma (NSCLC), the abelson murine leukemia viral oncogene homolog (ABL) kinase inhibitor imatinib against chronic myelogenous leukemias harboring the BCR-ABL fusion oncogene, and BRAF inhibitors (dabrafenib and vemurafenib) for the treatment of melanoma with V600E or V600K BRAF mutations1,3,4. This evidence concerns the gene EGFR and chronic myelogenous leukemia, BCR-ABL1 positive.